Distant metastasis from papillary thyroid carcinoma (PTC), particularly from papillary thyroid microcarcinoma, is rare. We present a case of perigastric lymph node metastasis from PTC in a patient with early gastric cancer and breast cancer. During post-surgical follow-up for breast cancer, a 56-year-old woman was diagnosed incidentally with early gastric cancer and synchronous left thyroid cancer. Therefore, laparoscopic distal gastrectomy with lymph node dissection and left thyroidectomy were performed. On the basis of the pathologic findings of the surgical specimens, the patient was diagnosed to have papillary thyroid microcarcinoma with perigastric lymph node metastasis and early gastric cancer with mucosal invasion. Finally, on the basis of immunohistochemical staining with galectin-3, the diagnosis of perigastric lymph node metastasis from PTC was made. When a patient has multiple primary malignancies with lymph node metastasis, careful pathologic examination of the surgical specimen is necessary; immunohistochemical staining may be helpful in determining the primary origin of lymph node metastasis.
Introduction
Thyroid cancer is a common malignancy worldwide. The prognosis of differentiated thyroid cancer, including papillary thyroid carcinoma (PTC) and follicular carcinoma, is favorable, with patients achieving long-term survival, except in some unusual cases. 1 The incidence of distant metastasis from differentiated thyroid cancer is low, with distant metastasis from PTC, particularly from papillary thyroid microcarcinoma, being especially rare. The most common sites of distant metastasis from thyroid cancer are the lung and bone, and less common sites of distant metastasis from differentiated thyroid cancer include the brain, breast, liver, and kidney. 2 However, there are no reports of patients with perigastric lymph node metastasis from PTC.
Herein, we present the case of a patient with early gastric cancer who was diagnosed with PTC with perigastric lymph node metastasis. To the best of our knowledge, this is the first reported case of perigastric lymph node metastasis from PTC.
Case Report
A 56-year-old woman was referred to our hospital for the surgical treatment of gastric cancer in September 2006. She had a medical history of hypothyroidism, and 3 months before, she had undergone lumpectomy with axillary lymph node dissection for left breast invasive ductal carcinoma at a different hospital. During a follow-up esophagogastroduodenoscopy, she was diagnosed incidentally with early gastric cancer (Fig. 1) . Endoscopic biopsy revealed moderately differentiated tubular adenocarcinoma in the midbody of the anterior abdominal wall. Abdominal computed tomography (CT) revealed neither regional lymph node metastasis nor distant metastasis. Because the patient had a history of hypothyroidism, we performed ultrasonography for further evaluation of the thyroid. A small calcified mass was detected in the upper pole of the left thyroid gland (Fig. 2) , and fine-needle aspiration biopsy (FNAB) was performed to rule out thyroid malignancy. ses. All lymph nodes with metastases were located along the lesser curvature of the stomach. Initially, we theorized that the perigastric lymph node metastases had originated from gastric cancer; therefore, the TNM stage of the gastric cancer was determined to be T1aN2M0 (6th American Joint Committee on Cancer TNM staging system). Because multiple lymph node metastases from early gas- (Fig. 5) . Finally, we confirmed that the perigastric lymph node metastases originated from thyroid cancer.
After thyroidectomy, the patient was administered Synthroid.
She was discharged without complications on postoperative day 10. Thus far, the patient has been alive for 8 years postoperatively, without recurrence of gastric, breast, or thyroid cancer.
Discussion
PTC is usually characterized by slow progression and is associated with long-term survival. High 10-year survival rates of 80?90% have been reported for patients with differentiated thyroid carcinoma. 1 Although lymph node metastasis from differentiated thyroid carcinoma occurs frequently, the incidence of distant metastasis from differentiated thyroid cancer is low, ranging from 4% to 15%, with variations in this rate for PTC and follicular thyroid carcinoma.
2,3 Shaha et al. 2 reported that the incidence of distant metastasis was only 2.3% in patients with PTC, but was 11% in patients with follicular carcinoma.
The most common sites of distant metastasis from thyroid cancer are the lung and bone, whereas less common sites of distant metastasis from PTC include the brain, breast, liver, kidney, adrenal gland, ovary, muscle, skin, stomach, or axillary lymph nodes. 4, 5 However, there are no cases of patients with perigastric lymph node metastasis from PTC. Early gastric cancer is defined as tumor invasion into the mucosal and submucosal layers of the stomach with or without lymph node metastasis. Although the rate of lymph node metastasis for early gastric cancer is approximately 20% in patients with submucosal cancer, this rate for mucosal cancer is ＜5%. 6 Our patient had a 1.5-cm mucosal gastric cancer with no lymphovascular invasion; therefore, the probability lymph node metastasis was very low.
After additional review and immunohistochemical staining (which was positive for galectin-3), the final pathologic report revealed that the perigastric lymph node metastases had originated from the PTC.
Perigastric lymph nodes typically drain lymphatic fluid from the stomach; therefore, most of such metastases originate from the stomach, which is an unusual site for metastasis from other malignancies. Although some studies have reported metastases to the stomach, they are few in number. 7 Oda et al. 8 studied metastases
to the stomach in 347 autopsy cases, and of these metastases cases, only 6.4% (7 cases in 110 autopsies) originated from a primary thyroid cancer. In our patient, we initially theorized that the perigastric lymph node metastases originated from metastatic gastric cancer.
However, the cellular morphology of the gastric cancer cells differed from that of the thyroid cancer cells; therefore, this theory was rejected.
Galectin-3 plays a role in the regulation of apoptosis, cell motility, and T-cell growth, and is also associated with tumor progression in thyroid cancer. The sensitivity and specificity of galectin-3 immunohistochemical staining alone in discriminating benign from malignant thyroid lesions is greater than 90% and 98%, respectively, and its diagnostic accuracy is 99%. Cytoplasmic galectin-3 expression on immunohistochemical staining could be a reliable marker for diagnosing PTC. 9 In our patient, metastatic perigastric lymph nodes were positive for galectin-3. Therefore, the final diagnosis of perigastric lymph node metastasis originating from PTC was based on the microscopic findings of the samples after hematoxylineosin staining and strong cytoplasmic staining for galectin-3 on immunohistochemistry.
In summary, our patient had metachronous breast cancer, synchronous PTC, and early gastric cancer (triple cancer), with the rare finding of perigastric lymph node metastases from PTC rather than from gastric cancer. The definitive diagnosis of perigastric lymph node metastases from PTC could be made after immunohistochemical staining for galectin-3. Therefore, when a patient with PTC undergoes additional surgical resection for a distinct pathologic problem, it is necessary to carefully determine the histologic diagnosis of all specimens and to consider the possibility of distant metastasis from the PTC.
To our knowledge, this is the first reported case of perigastric lymph node metastases from PTC in a patient with early gastric cancer.
